Literature DB >> 21989859

Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers.

Kathrin Brockmann1, Adriane Gröger, Adriana Di Santo, Inga Liepelt, Claudia Schulte, Uwe Klose, Walter Maetzler, Ann-Kathrin Hauser, Ruediger Hilker, Baltazar Gomez-Mancilla, Daniela Berg, Thomas Gasser.   

Abstract

The objective of this research was to evaluate a possible endophenotype in leucine-rich repeat kinase 2 (LRRK2)-associated Parkinson's disease (PD). Ten symptomatic LRRK2 patients, 24 sporadic Parkinson's disease patients as well as 10 asymptomatic LRRK2 mutation carriers and 29 matched healthy controls underwent comprehensive clinical assessments with respect to motor and non-motor symptoms. Transcranial sonography and magnetic resonance imaging (voxel-based morphometry [VBM]) were assessed to evaluate morphological imaging characteristics. LRRK2 patients had an earlier onset of motor symptoms and a more benign phenotype of motor and non-motor characteristics compared to sporadic Parkinson's disease patients. However, depression scores were higher in LRRK2 patients. No clinical differences were found regarding motor and non-motor symptoms in asymptomatic LRRK2 mutation carriers in comparison to controls. Transcranial sonography showed hyperechogenicity of the substantia nigra in both patients' cohorts as well as in asymptomatic LRRK2 mutation carriers. Voxel-based morphometry revealed increased gray matter volume of the cerebellum and precentral gyrus in LRRK2 patients and of the cuneus in asymptomatic LRRK2 mutation carriers. In contrast, we found decreased basal ganglia gray matter volume in LRRK2 patients compared to controls. Increased gray matter volume of different anatomical structures associated with motor loops in LRRK2 patients and asymptomatic LRRK2 mutation carriers compared to age-matched sporadic Parkinson's disease patients and controls might indicate compensatory mechanism in LRRK2 mutation carriers due to motor network plasticity not only in the symptomatic stage of the disease but even in the premotor phase. Substantia nigra hyperechogenicity in yet unaffected LRRK2 mutation carriers indicates morphologic alterations in an asymptomatic stage of disease.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21989859     DOI: 10.1002/mds.23991

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  16 in total

Review 1.  LRRK2 in Parkinson disease: challenges of clinical trials.

Authors:  Eduardo Tolosa; Miquel Vila; Christine Klein; Olivier Rascol
Journal:  Nat Rev Neurol       Date:  2020-01-24       Impact factor: 42.937

Review 2.  [Genetic risk variants in Parkinson's disease and other movement disorders].

Authors:  K Brockmann; K Lohmann
Journal:  Nervenarzt       Date:  2017-07       Impact factor: 1.214

3.  Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers.

Authors:  Rick C Helmich; Avner Thaler; Bart F L van Nuenen; Tanya Gurevich; Anat Mirelman; Karen S Marder; Susan Bressman; Avi Orr-Urtreger; Nir Giladi; Bastiaan R Bloem; Ivan Toni
Journal:  Neurology       Date:  2014-12-24       Impact factor: 9.910

Review 4.  The presymptomatic phase of amyotrophic lateral sclerosis: are we merely scratching the surface?

Authors:  Rangariroyashe H Chipika; We Fong Siah; Mary Clare McKenna; Stacey Li Hi Shing; Orla Hardiman; Peter Bede
Journal:  J Neurol       Date:  2020-10-31       Impact factor: 6.682

Review 5.  Olfactory dysfunction: common in later life and early warning of neurodegenerative disease.

Authors:  Karl-Bernd Hüttenbrink; Thomas Hummel; Daniela Berg; Thomas Gasser; Antje Hähner
Journal:  Dtsch Arztebl Int       Date:  2013-01-07       Impact factor: 5.594

6.  Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers.

Authors:  Claustre Pont-Sunyer; Alex Iranzo; Carles Gaig; Ana Fernández-Arcos; Dolores Vilas; Francesc Valldeoriola; Yaroslau Compta; Ruben Fernández-Santiago; Manel Fernández; Angels Bayés; Matilde Calopa; Pilar Casquero; Oriol de Fàbregues; Serge Jaumà; Victor Puente; Manel Salamero; Maria José Martí; Joan Santamaría; Eduard Tolosa
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

Review 7.  The role of the LRRK2 gene in Parkinsonism.

Authors:  Jie-Qiong Li; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurodegener       Date:  2014-11-12       Impact factor: 14.195

8.  Nonmotor symptoms in LRRK2 G2019S associated Parkinson's disease.

Authors:  Carles Gaig; Dolores Vilas; Jon Infante; María Sierra; Inés García-Gorostiaga; Mariateresa Buongiorno; Mario Ezquerra; Maria José Martí; Francesc Valldeoriola; Miquel Aguilar; Matilde Calopa; Jorge Hernandez-Vara; Eduardo Tolosa
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

9.  The effect of the PARK16 rs11240572 variant on brain structure in Parkinson's disease.

Authors:  Lu-Yan Gu; Shao-Bing Dai; Cheng Zhou; Ting Gao; Jing-Jing Wu; Yi Fang; Xiao-Jun Guan; Tao Guo; Ran Zheng; Chongyao Jin; Xiao-Jun Xu; Zhe Song; Jun Tian; Xinzhen Yin; Min-Min Zhang; Bao-Rong Zhang; Yaping Yan; Jiali Pu
Journal:  Brain Struct Funct       Date:  2021-08-09       Impact factor: 3.270

10.  Inflammatory profile in LRRK2-associated prodromal and clinical PD.

Authors:  Kathrin Brockmann; Anja Apel; Claudia Schulte; Nicole Schneiderhan-Marra; Claustre Pont-Sunyer; Dolores Vilas; Javier Ruiz-Martinez; Markus Langkamp; Jean-Christophe Corvol; Florence Cormier; Thomas Knorpp; Thomas O Joos; Thomas Gasser; Birgitt Schüle; Jan O Aasly; Tatiana Foroud; Jose Felix Marti-Masso; Alexis Brice; Eduardo Tolosa; Connie Marras; Daniela Berg; Walter Maetzler
Journal:  J Neuroinflammation       Date:  2016-05-24       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.